{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:52:54Z","timestamp":1792641174287,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/1469-0691.12568","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T12:52:45Z","timestamp":1390999965000},"page":"37-44","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S5","title":["Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices"],"prefix":"10.1016","volume":"20","author":[{"given":"S.","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gairola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12568_bib2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/1469-0691.12568_bib3","first-page":"3176","article-title":"Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all","volume":"18","author":"Pagliusi","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib4","doi-asserted-by":"crossref","first-page":"B184","DOI":"10.1016\/j.vaccine.2012.12.032","article-title":"Delivering the promise of decade of the vaccines: opportunities and challenges in the development of high quality vaccines","volume":"31","author":"Keith","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib6","first-page":"14","article-title":"Vaccine market revenue growing emerging countries are outperforming U.S., racking up double-digit growth","volume":"31","author":"Carlson","year":"2011","journal-title":"Gen Eng Biotechnol News"},{"key":"10.1111\/1469-0691.12568_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1478-4505-10-18","article-title":"Emergence of biopharmaceutical innovators in China, India, Brazil and South Africa as global competitors and collaborators","volume":"10","author":"Rezale","year":"2012","journal-title":"Health Res Policy Syst"},{"key":"10.1111\/1469-0691.12568_bib9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2009.12.036","article-title":"The role of emerging manufacturers in access to innovative vaccines of public health importance","volume":"28","author":"Milstein","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biologicals.2009.02.009","article-title":"Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status","volume":"37","author":"Jadhav","year":"2009","journal-title":"Biologicals"},{"key":"10.1111\/1469-0691.12568_bib14","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.vaccine.2013.04.082","article-title":"Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012","volume":"31","author":"Pagliusi","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib15","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/infdis\/jir075","article-title":"The measles initiative: moving toward measles eradication","volume":"204","author":"Christie","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12568_bib16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.vaccine.2013.02.047","article-title":"A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome","volume":"31","author":"Mongua-Rodriguez","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib17","first-page":"27","article-title":"Global control and regional elimination of measles, 2000\u20132011","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1111\/1469-0691.12568_bib18","author":"GAVI Alliance"},{"key":"10.1111\/1469-0691.12568_bib19","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2011.10.005","article-title":"The global polio eradication initiative: lessons learned and prospects for success","volume":"29","author":"Aylward","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib20","first-page":"344","article-title":"India reaches milestone of no cases of wild poliovirus for 12 months","volume":"23","author":"Kaura","year":"2012","journal-title":"BMJ"},{"key":"10.1111\/1469-0691.12568_bib21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.vaccine.2011.11.018","article-title":"Intradermal fractional dose inactivated polio vaccine: a review of the literature","volume":"30","author":"Nelson","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib23","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","article-title":"The meningitis vaccine project","volume":"3","author":"LaForce","year":"2007","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib25","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1016\/j.vaccine.2012.09.008","article-title":"Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the meningitis vaccine project","volume":"30","author":"Marchetti","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib26","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12568_bib28","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.vaccine.2011.02.079","article-title":"WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer","volume":"29","author":"Friede","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.provac.2010.07.010","article-title":"Influenza vaccine production capacity building in developing countries: example of the serum institute of India","volume":"2","author":"Jadhav","year":"2010","journal-title":"Proc Vaccinol"},{"key":"10.1111\/1469-0691.12568_bib30","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1016\/j.vaccine.2011.09.049","article-title":"Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets","volume":"29","author":"Stittelaar","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib31","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2011.04.119","article-title":"A pandemic influenza vaccine in India: from strain to sale within 12 months","volume":"29","author":"Dhere","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib32","author":"Milstein"},{"key":"10.1111\/1469-0691.12568_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4161\/hv.23163","article-title":"Vaccinology capacity building in Europe for innovative platforms serving emerging markets","volume":"9","author":"Hendriks","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1111\/1469-0691.12568_bib34","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/j.vaccine.2012.05.058","article-title":"Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries","volume":"30","author":"Beurret","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib35","first-page":"6230","article-title":"Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field","volume":"30","author":"Hendriks","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12568_bib36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1377\/hlthaff.2011.0338","article-title":"Vaccines as a global imperative: a business perspective","volume":"30","author":"Stephenne","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1111\/1469-0691.12568_bib37","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1377\/hlthaff.2011.0295","article-title":"Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa","volume":"30","author":"Bishal","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1111\/1469-0691.12568_bib38","first-page":"556","article-title":"Reaching International GMP standards for vaccine production: challenges for developing countries","volume":"8","author":"Milstein","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1111\/1469-0691.12568_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1377\/hlthaff.2011.0361","article-title":"Challenges to building capacity for evidence based new vaccine policy in developing countries","volume":"30","author":"Andrus","year":"2011","journal-title":"Health Aff (Millwood)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T03:47:02Z","timestamp":1565149622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14601749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":32,"alternative-id":["S1198743X14601749"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12568","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}